aztreonam has been researched along with Genetic Predisposition in 2 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Torres, E | 1 |
| Villanueva, R | 1 |
| Bou, G | 1 |
| Mogayzel, PJ | 1 |
| Flume, PA | 1 |
1 review available for aztreonam and Genetic Predisposition
| Article | Year |
|---|---|
Update in cystic fibrosis 2009.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Child; Child, Preschool; Cystic Fibrosis; Genetic Predispos | 2010 |
1 other study available for aztreonam and Genetic Predisposition
| Article | Year |
|---|---|
Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Automation; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; G | 2009 |